0001193805-21-000126.txt : 20210203 0001193805-21-000126.hdr.sgml : 20210203 20210203170140 ACCESSION NUMBER: 0001193805-21-000126 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20210203 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210203 DATE AS OF CHANGE: 20210203 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ADMA BIOLOGICS, INC. CENTRAL INDEX KEY: 0001368514 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 562590442 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36728 FILM NUMBER: 21587035 BUSINESS ADDRESS: STREET 1: C/O ADMA BIOLOGICS, INC. STREET 2: 465 STATE ROUTE 17 CITY: RAMSEY STATE: NJ ZIP: 07446 BUSINESS PHONE: (201) 478-5552 MAIL ADDRESS: STREET 1: C/O ADMA BIOLOGICS, INC. STREET 2: 465 STATE ROUTE 17 CITY: RAMSEY STATE: NJ ZIP: 07446 FORMER COMPANY: FORMER CONFORMED NAME: R&R ACQUISITION VI, INC DATE OF NAME CHANGE: 20060707 8-K 1 e620246_8k-adma.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 3, 2021

ADMA BIOLOGICS, INC.
(Exact name of registrant as specified in its charter)

Delaware	001-36728	56-2590442
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

465 State Route 17, Ramsey, New Jersey		07446
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (201) 478-5552

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	ADMA	Nasdaq Global Market
Preferred Stock Purchase Rights	—	Nasdaq Global Market

Item 1.01

Entry into a Material Definitive Agreement

Amendment No. 2 to the Open Market Sale Agreement^SM

ADMA Biologics, Inc. (the “Company”) is a party to the Open Market Sale Agreement^SM, dated August 5, 2020, with Jefferies LLC (“Jefferies”), which was previously amended by Amendment No. 1 to the Open Market Sale Agreement^SM, dated November 5, 2020, by and between the Company and Jefferies (as so amended, the “Prior Sale Agreement”). Pursuant to the Prior Sale Agreement, the Company could offer to sell, from time to time through Jefferies, shares of the Company’s common stock (the “Shares”) having an aggregate offering price of up to $70.0 million.

On February 3, 2021, the Company and Jefferies entered into Amendment No. 2 to the Open Market Sale Agreement^SM (“Amendment No. 2” and together with the Prior Sale Agreement, the “Amended Sale Agreement”) to provide for an increase in the aggregate offering amount under the Prior Sale Agreement, such that as of February 3, 2021, the Company may offer and sell Shares having an additional aggregate offering price of up to approximately $35.4 million under the Amended Sale Agreement, by methods deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended.

Subject to the terms of the Amended Sale Agreement, Jefferies will use commercially reasonable efforts to sell the Shares from time to time (the Offering”), based upon the Company’s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company cannot provide any assurances that it will issue any additional Shares pursuant to the Amended Sale Agreement. The Company will pay Jefferies a commission of up to 3.0% of the gross proceeds from the sale of the Shares, if any. The Company has also agreed to provide Jefferies with customary indemnification rights. The offering of the Shares will terminate upon the earliest of (a) the sale of the maximum number or amount of the Shares permitted to be sold under the Amended Sale Agreement and (b) the termination of the Amended Sale Agreement by the parties thereto.

The foregoing description of the Amended Sale Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of Amendment No. 2, which is filed herewith as Exhibit 1.1 and incorporated by reference herein.

Item 8.01

Other Events

Certain Preliminary Financial Results as of December 31, 2020

Based upon this Amended Sale Agreement, the Company's current projected revenue and expenditures, including capital expenditures and continued implementation of the Company's commercialization, expansion activities and the proceeds from the Offering, as well as certain other assumptions, the Company currently believes that the Company's cash, cash equivalents, projected revenue and accounts receivable will be sufficient to fund the Company's operations, as currently conducted, now into the fourth quarter of 2021. The Company’s preliminary, unaudited revenues for the fourth quarter 2020 and for the full year 2020, were $13.9 million and $42.2 million of revenues, respectively. Additionally, as of December 31, 2020, the Company’s preliminary, unaudited cash and cash equivalents totaled $55.9 million. In order to have sufficient cash to fund the Company’s operations thereafter, the Company anticipates it will need to raise additional capital before the end of the fourth quarter of 2021. The Company has prepared these estimates on the basis of currently available information; however these estimates are preliminary and are subject to completion of financial closing procedures that could result in changes to these amounts and do not present all information necessary for an understanding of the Company’s results of operations for the fourth quarter or full year 2020. These preliminary estimates have been prepared by, and are the responsibility of, the Company’s management. The Company’s independent registered public accounting firm, CohnReznick LLP, has not audited or reviewed, and does not express an opinion with respect to, these estimates. Complete annual results will be included in our Annual Report on Form 10-K for the year ended December 31, 2020. Additionally, these estimates may change based upon several factors, including the success of the Company’s commercial sales of its products, manufacturing ramp-up activities, the acceptability of its immune globulin products by physicians, patients or payers and the various financing options that may be available to the Company. In addition, the Company’s end-to-end production cycle from procurement of raw materials to commercial release of finished product can take between seven and 12 months or potentially longer, requiring substantial investments in raw material plasma and other manufacturing materials. For further information, see the risks and uncertainties described in the Company’s filings with the U.S. Securities and Exchange Commission, including its most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about the Company. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as “estimate,” “project,” “intend,” “forecast,” “target,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “should,” “could,” “would,” “may,” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements also include, but are not limited to, statements about the Company’s future results of operations; the Company’s expectations regarding the sufficiency of its cash, cash equivalents, projected revenues and accounts receivable to fund its operations; timing of revenue and profitability and execution of corporate objectives and achievement of goals. Actual events or results may differ materially from those described in this document due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this Current Report on Form 8-K will prove to be accurate. Except to the extent required by applicable laws or rules, the Company does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause the Company’s actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties described in the Company’s filings with the U.S. Securities and Exchange Commission, including its most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.

Item 9.01

Exhibits.

(d) Exhibits

Exhibit No.

Description

	1.1	Amendment No. 2 to Sale Agreement, dated as of February 3, 2021
	5.1	Opinion of Morgan, Lewis & Bockius LLP
	23.1	Consent of Morgan, Lewis & Bockius LLP (included in Exhibit 5.1)
	104	Cover Page Interactive Data File (embedded with the Inline XBRL Document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

February 3, 2021	ADMA Biologics, Inc.


	By:	/s/ Brian Lenz
		Name:	Brian Lenz
		Title:	Executive Vice President and Chief Financial Officer

EX-1.1 2 e620246_ex1-1.htm

AMENDMENT NO. 2 TO THE OPEN MARKET SALE AGREEMENT^SM

February 3, 2021

JEFFERIES LLC

520 Madison Avenue

New York, New York 10022

Ladies and Gentlemen:

This Amendment No. 2 to the Open Market Sale Agreement^SM (this “Amendment”) is entered into as of the date first written above by ADMA Biologics, Inc., a Delaware corporation (the “Company”), and Jefferies LLC as sales agent and/or principal (the “Agent”) that together are the parties to that certain Open Market Sale Agreement^SM, dated August 5, 2020, as amended by Amendment No. 1 to the Open Market Sale Agreement^SM, dated November 5, 2020 (the “Original Agreement”). All capitalized terms not defined herein shall have the meanings ascribed to them in the Original Agreement. The parties hereto, intending to be legally bound, hereby agree as follows:

1.

The preamble to the Original Agreement is hereby deleted in its entirety and replaced with the following:

“ADMA Biologics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), having an aggregate offering price of up to $105,412,500 on the terms set forth in this agreement (this “Agreement”).”

2.

The definition of “Maximum Program Amount” in Section 1(a) of the Original Agreement is hereby deleted in its entirety and replaced with the following:

“Maximum Program Amount” means Common Shares with an aggregate Sales Price of the lesser of (a) $105,412,500, (b) the number or dollar amount of Common Shares registered under the effective Registration Statement (defined below) pursuant to which the offering is being made, (c) the number of authorized but unissued Common Shares (less Common Shares issuable upon exercise, conversion or exchange of any outstanding securities of the Company or otherwise reserved from the Company’s authorized capital stock), (d) the number or dollar amount of Common Shares permitted to be sold under Form S-3 (including General Instruction I.B.6 thereof, if applicable), or (e) the number or dollar amount of Common Shares for which the Company has filed a Prospectus (defined below).”

3.

The Company shall file a Prospectus Supplement pursuant to Rule 424(b) under the Securities Act reflecting this Amendment and disclose this Amendment in a Current Report on Form 8-K within one (1) Business Day following the date hereof.

4.

The Company agrees to pay all costs, fees and expenses incurred in connection with entering into this Amendment and the performance of the Company’s obligations under the Original Agreement as amended by this Amendment and the transactions contemplated hereby and thereby, including without limitation, (i) all filing fees, attorneys’ fees and expenses incurred by the Company or any Agent in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Shares authorized by this Amendment for offer and sale under the state securities or blue sky laws or the provincial securities laws of Canada, and, if requested by an Agent, preparing and printing a “Blue Sky Survey” or memorandum and a “Canadian wrapper” and any supplements thereto, advising the Agent of such qualifications, registrations, determinations and exemptions and (ii) the reasonable fees and disbursements of the Agent’s counsel, including the reasonable fees and expenses of counsel for the Agent in connection with, FINRA review, if any, and approval of the Agent’s participation in the offering and distribution of the Shares authorized by this Amendment. The fees and disbursements of Agent’s counsel pursuant to subsections (i) and (ii) above shall not exceed $50,000. For the avoidance of doubt, the $50,000 of fees and disbursements of Agent’s counsel that may become payable by the Company hereunder shall be in addition to the fees and disbursements of Agent’s counsel in connection with entering into the Original Agreement and the first amendment thereto that were payable by the Company under Section 3(d) of the Agreement and up to $15,000 of fees and disbursements of Agent’s Counsel that may become payable by the Company pursuant to Section 3(d) of the Agreement in connection with each Triggering Event Date on which the Company is required to provide a certificate pursuant to Section 4(o) of the Agreement.

5.

The Company represents and warrants to, and agrees with the Agent that as of the date of this Amendment, this Amendment has been duly authorized, executed and delivered by, and is a valid and binding agreement of, the Company, enforceable in accordance with its terms, except as rights to indemnification hereunder may be limited by applicable law and except as the enforcement hereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of creditors or by general equitable principles.

6.

This Amendment, together with the Original Agreement, constitutes the entire agreement of the parties hereto and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Amendment may not be amended or modified unless in writing by all the parties hereto, and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit. The invalidity or unenforceability of any provision contained herein shall not affect the validity or enforceability of any other provision hereof. If any provision of this Amendment is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable. All references in the Original Agreement to the “Agreement” shall mean the Original Agreement as amended by this Amendment; provided, however, that all references to “date of this Agreement” in the Original Agreement shall continue to refer to the date of the Original Agreement.

7.

This Amendment shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of or based upon this Amendment or the transactions contemplated hereby or by the Original Agreement may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case located in the Borough of Manhattan in the City of New York (collectively, the “Specified Courts”), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to such party’s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum.

8.

This Amendment may be executed in any number of counterparts, each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same instrument. Delivery of an executed amendment by one party to the other may be made by facsimile, electronic mail or other transmission method as permitted by applicable law, and the parties hereto agree that any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. A party’s electronic signature (complying with the New York Electronic Signatures and Records Act (N.Y. State Tech. §§ 301-309), as amended from time to time, or other applicable law) of this Agreement shall have the same validity and effect as a signature affixed by the party’s hand.

[Remainder of Page Intentionally Blank]

If the foregoing correctly sets forth the understanding between the Company and the Agent, please so indicate in the space provided below for that purpose, whereupon this Amendment shall constitute a binding amendment to the Original Agreement between the Company and the Agent.

Very truly yours,

JEFFERIES LLC

By:	/s/ Michael Magarro
Name:	Michael Magarro
Title:	Managing Director

ACCEPTED as of the date first-above written:

ADMA BIOLOGICS, INC.

By:	/s/ Adam Grossman
Name:	Adam Grossman
Title:	President and Chief Executive Officer

[Signature Page to Amendment No. 2 to the Open Market Sale Agreement^SM]

EX-5.1 3 e620246_ex5-1.htm

February 3, 2021

ADMA Biologics, Inc.
465 State Route 17
Ramsey, NJ 07446

Re:

ADMA Biologics, Inc. Registration Statement on Form S-3 (333-234107)

Ladies and Gentlemen:

We have acted as counsel to ADMA Biologics, Inc., a Delaware corporation (the “Company”), in connection with the filing of a prospectus supplement, dated February 3, 2021 (the “Prospectus”), by the Company with the Securities and Exchange Commission (the “Commission”) on February 3, 2021 pursuant to Rule 424(b)(5) of the Securities Act of 1933, as amended (the “Act”), relating to the offer and sale by the Company of up to $35,412,500 aggregate offering amount of shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), in an “at the market offering” as defined in Rule 415(a)(4) of the Act in accordance with the Open Market Sale Agreement^SM, dated August 5, 2020 (the “Sale Agreement”), by and between the Company and Jefferies LLC (the “Agent”), as amended by Amendment No. 1 to the Open Market Sale Agreement^SM, dated as of November 5, 2020, by and between the Company and the Agent (“Amendment No. 1”) and further amended by Amendment No. 2 to the Open Market Sale Agreement^SM, dated as of February 3, 2021, by and between the Company and the Agent (“Amendment No. 2” and together with the Sale Agreement, as amended by Amendment No. 1, the “Amended Sale Agreement”), pursuant to the referenced Registration Statement on Form S-3 (No. 333-234107) (the “Registration Statement”) filed with the Commission on October 4, 2019 and declared effective on October 15, 2019.

As to all matters of fact (including factual conclusions and characterizations and descriptions of purpose, intention or other state of mind), we have relied, with your permission, entirely upon written actions by the Board of Directors of the Company and certificates of certain officers of the Company and have assumed, without independent inquiry, the accuracy of those certificates and written actions by the Board of Directors of the Company.

As counsel to the Company, in rendering the opinions hereinafter expressed, we have examined and relied upon originals or copies of such corporate records, agreements, documents and instruments as we have deemed necessary or advisable for purposes of this opinion, including (i) the certificate of incorporation and bylaws of the Company, (ii) the Registration Statement and the exhibits thereto filed with the Commission, (iii) the Prospectus, (iv) the Amended Sale Agreement and (v) the written actions of the Board of Directors of the Company referenced above.

	Morgan, Lewis & Bockius llp

	502 Carnegie Center
	Princeton, NJ 08540-6241	+1.609.919.6600
	United States	+1.609.919.6701

ADMA Biologics, Inc.

February 3, 2021

Page 2

This opinion is limited solely to the Delaware General Corporation Law without regard to choice of law, to the extent that the same may apply to or govern the transactions contemplated by the Registration Statement. We express no opinion as to the effect of events occurring, circumstances arising, or changes of law becoming effective or occurring, after the date hereof on the matters addressed in this opinion.

Based on such examination and subject to the foregoing, we are of the opinion that the Shares, when issued by the Company and delivered by the Company against payment therefor as contemplated by the Amended Sale Agreement, and an Issuance Notice (as defined in the Amended Sale Agreement), will be validly issued, fully paid and non-assessable.

We hereby consent to the filing of this opinion letter as Exhibit 5.1 to the Registration Statement and to the reference to us under the caption “Legal Matters” in the Prospectus. In giving this consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Act, or the rules and regulations of the Commission thereunder. In rendering this opinion, we are opining only as to the specific legal issues expressly set forth herein, and no opinion shall be inferred as to any other matter or matters. This opinion is intended solely for use in connection with the issuance and sale of the Shares subject to the Registration Statement and is not to be relied upon for any other purpose.

Very truly yours,

/s/ Morgan, Lewis & Bockius LLP

EX-101.SCH 4 adma-20210203.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 adma-20210203_def.xml XBRL TAXONOMY EXTENSION DEFINITION EX-101.LAB 6 adma-20210203_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Common Stock [Member] Preferred Stock Purchase Rights Statement [Table] Schedule of Capitalization, Equity [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 adma-20210203_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION GRAPHIC 8 image.jpg GRAPHIC begin 644 image.jpg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end GRAPHIC 9 image_001.jpg GRAPHIC begin 644 image_001.jpg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end GRAPHIC 10 image_002.jpg GRAPHIC begin 644 image_002.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# (! 0(! 0(" @(" @(" P4# P,# M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_ MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P, M# P,# P,# P,# P,# P,# P,# P,# S_P 1" - X# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#SM?BI_P - MO^$?VH_CG\<)(;WQ9\,O$]A8^$M-\1>--3\/6/AD7 O_ /0[0688&Z4V\21H MR@/(I+N"S,?U%_X-M_VKO'?[6O\ P3;MM2^(-_?ZSK'A7Q#=>';?5K]F>ZU6 MUB@MIHY97/WV4W#Q;LDGR1DEMQK>_:J_X-__ (!_M9?$_5O%&HGQSX4E\37Z M:KXBTWPUK8L]+\1W:%BL]U;O'(ADRSG?'L;+NV=S,3]5?L^_L^>#_P!ECX0: G+X#\!Z);>'O"WA^(PV=E"6;;N8N[LS$L[LS,S,Q)8L2304VK'__9 end XML 11 e620246_8k-adma_htm.xml IDEA: XBRL DOCUMENT 0001368514 2021-02-03 2021-02-03 0001368514 us-gaap:CommonStockMember 2021-02-03 2021-02-03 0001368514 ADMA:PreferredStockPurchaseRightsMember 2021-02-03 2021-02-03 iso4217:USD shares iso4217:USD shares 0001368514 false true 8-K 2021-02-03 ADMA BIOLOGICS, INC. DE 001-36728 56-2590442 465 State Route 17 Ramsey NJ 07446 (201) 478-5552 false false false false false Common Stock ADMA NASDAQ Preferred Stock Purchase Rights NASDAQ XML 12 R1.htm IDEA: XBRL DOCUMENT

Cover	Feb. 03, 2021
Schedule of Capitalization, Equity [Line Items]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Feb. 03, 2021
Entity File Number	001-36728
Entity Registrant Name	ADMA BIOLOGICS, INC.
Entity Central Index Key	0001368514
Entity Tax Identification Number	56-2590442
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	465 State Route 17
Entity Address, City or Town	Ramsey
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07446
City Area Code	(201)
Local Phone Number	478-5552
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Common Stock [Member]
Schedule of Capitalization, Equity [Line Items]
Title of 12(b) Security	Common Stock
Trading Symbol	ADMA
Security Exchange Name	NASDAQ
Preferred Stock Purchase Rights
Schedule of Capitalization, Equity [Line Items]
Title of 12(b) Security	Preferred Stock Purchase Rights
No Trading Symbol Flag	true
Security Exchange Name	NASDAQ

EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 3 96 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://admabiologics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports e620246_8k-adma.htm adma-20210203.xsd adma-20210203_def.xml adma-20210203_lab.xml adma-20210203_pre.xml e620246_ex1-1.htm e620246_ex5-1.htm http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "e620246_8k-adma.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "adma-20210203_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "e620246_8k-adma.htm" ] }, "labelLink": { "local": [ "adma-20210203_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "adma-20210203_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "adma-20210203.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 65, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 1, "memberStandard": 1, "nsprefix": "ADMA", "nsuri": "http://admabiologics.com/20210203", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "e620246_8k-adma.htm", "contextRef": "From2021-02-03to2021-02-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://admabiologics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "e620246_8k-adma.htm", "contextRef": "From2021-02-03to2021-02-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "ADMA_PreferredStockPurchaseRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock Purchase Rights" } } }, "localname": "PreferredStockPurchaseRightsMember", "nsuri": "http://admabiologics.com/20210203", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfCapitalizationEquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Capitalization, Equity [Line Items]" } } }, "localname": "ScheduleOfCapitalizationEquityLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://admabiologics.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 19 0001193805-21-000126-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193805-21-000126-xbrl.zip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